Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).


Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 17 07 2020
revised: 09 12 2020
accepted: 16 01 2021
pubmed: 26 1 2021
medline: 9 3 2021
entrez: 25 1 2021
Statut: ppublish

Résumé

To compare trimodality therapy (TMT) versus radical cystectomy (RC) and develop GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) for treatment of muscle-invasive bladder cancer (MIBC). Prospective and retrospective studies comparing TMT and RC for MIBC patients were included. Qualitative and quantitative evaluation of evidence was made. Ten studies were included in the analysis. Pooled analysis showed salvage cystectomy and pathological complete response rates after TMT of 12 % and 72-77.5 %, respectively. Pooled rates of G3-G4 GU toxicity and serious toxicity rate were 18 vs 3% and 45 vs 29 % for patients undergoing TMT vs RC, respectively. The panel assessed a substantial equivalence in terms of OS and CSS at 5 years between TMT and RC. TMT could be suggested as an alternative treatment to RC in non-metastatic MIBC patients, deemed fit for surgery.

Identifiants

pubmed: 33493633
pii: S1040-8428(21)00023-8
doi: 10.1016/j.critrevonc.2021.103235
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103235

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Giulio Francolini (G)

Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.

Simona Borghesi (S)

Radiation Oncology Arezzo-Valdarno, Azienda USL Toscana Sud Est, Arezzo, Italy. Electronic address: s.borghesi@gmail.com.

Sergio Fersino (S)

Radiotherapy Division, Santa Chiara Hospital, Trento, Italy.

Alessandro Magli (A)

Department of Radiation Oncology, Udine General Hospital, Udine, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.

Luca Cristinelli (L)

Urology Department, ASST Spedali Civili di Brescia, Brescia University, Italy.

Mimma Rizzo (M)

Division of Translational Oncology, IRCCS ICS Maugeri, Pavia, Italy.

Renzo Corvò (R)

Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino - Genoa and University of Genoa, Italy.

Giovanni L Pappagallo (GL)

Freelance Clinical Epidemiologist, Italy.

Stefano Arcangeli (S)

Department of Radiation Oncology, Ospedale S. Gerardo and University of Milan Bicocca, Milan, Italy.

Stefano Maria Magrini (SM)

Radiation Oncology Department, ASST Spedali Civili di Brescia, Brescia University, Italy.

Rolando M D'Angelillo (RM)

Radiation Oncology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH